Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Fineline Cube Jan 15, 2026
Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Fineline Cube Jan 15, 2026
Company Deals

Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy

Fineline Cube Jan 15, 2026
Company Deals

WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development

Fineline Cube Jan 15, 2026
Company Deals

WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic

Fineline Cube Jan 15, 2026
Company Drug

Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination

Fineline Cube Jan 15, 2026
Drug Policy / Regulatory

CDE Releases 65th Batch of Chemical Generic Reference Preparations

Fineline Cube Jan 3, 2023

The Center for Drug Evaluation (CDE) has released the 65th batch of chemical generic reference...

Company Drug Legal / IP

Viking Therapeutics Sues Ascletis Pharma Over Alleged Trade Secret Theft

Fineline Cube Jan 3, 2023

US – based Viking Therapeutics (NASDAQ: VKTX) is set to take China’s Ascletis Pharma Inc....

Company Deals

Shuwen Biotech Partners with Nottingham University Hospitals for MammaTyper

Fineline Cube Jan 3, 2023

China – based diagnostic specialist Shuwen Biotech Co., Ltd and its German wholly – owned...

Company Drug

Chinagene Tech’s ZVS101e Receives FDA IND Approval for Bietti’s Crystalline Dystrophy

Fineline Cube Jan 3, 2023

Beijing – based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has...

Drug Policy / Regulatory

Jiangxi Leads 16-Province VBP Alliance with Winning Bids Announced

Fineline Cube Jan 3, 2023

The Jiangxi Province Healthcare Security Administration has released a notification regarding the winning bids of...

Company Medical Device

NMPA Approves 172 Medical Devices for Marketing in November 2022

Fineline Cube Dec 30, 2022

The National Medical Products Administration (NMPA) approved 172 medical devices for marketing in November 2022....

Company Drug

Merck’s Lagevrio Receives Emergency Conditional Approval from China’s NMPA

Fineline Cube Dec 30, 2022

US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced receiving emergency conditional approval...

Policy / Regulatory

NHSA and CNIPA Issue Opinions on Strengthening IP Protection in Drug Procurement

Fineline Cube Dec 30, 2022

The National Healthcare Security Administration (NHSA) and the China National Intellectual Property Administration (CNIPA) have...

Company Drug

Legend Biotech’s Carvykti Accepted for Review by China’s CDE

Fineline Cube Dec 30, 2022

The Center for Drug Evaluation (CDE) website indicates that a market approval filing from Legend...

Company Deals

F-star Therapeutics and Sino Biopharmaceutical Face Delays in Proposed Acquisition

Fineline Cube Dec 30, 2022

UK-based biotech F-star Therapeutics (NASDAQ: FSTX) released an SEC filing indicating that the proposed acquisition...

Company Drug

CSPC’s ALMB-0168 Receives NMPA Approval for Osteoarthritis Clinical Study

Fineline Cube Dec 30, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...

Company Drug

RemeGen’s RC108 Receives FDA Go-Ahead for Phase I Clinical Study

Fineline Cube Dec 30, 2022

China-based biopharma RemeGen Ltd (HKG: 9995) has announced receiving approval from the US FDA to...

Company Drug

Simcere Receives NMPA Clearance for SIM0348 Clinical Study

Fineline Cube Dec 30, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...

Company Deals

Skynor Medical Raises RMB 100 Million in Financing Round for Market Expansion

Fineline Cube Dec 30, 2022

Skynor Medical, a Shanghai-based manufacturer of nerve and peripheral blood vessel implantation and interventional devices,...

Company Deals

Sichuan Kelun Completes RMB 1.5 Billion Financing Round for Kelun-Biotech

Fineline Cube Dec 30, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced the completion of a financing...

Company Drug

Everest Medicines’ Nefecon Receives Priority Review Recommendation from CDE

Fineline Cube Dec 30, 2022

China-based Everest Medicines (HKG: 1952) has announced that the Center for Drug Evaluation (CDE) of...

Company Drug

BrightGene Receives NMPA Approval for BGM0504 Clinical Trial

Fineline Cube Dec 30, 2022

China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has announced that it has received clinical...

Drug

Anhui Anke Biotechnology Receives NMPA Approval for AK2017 Clinical Study

Fineline Cube Dec 30, 2022

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced receiving approval from the...

Company Drug

AstraZeneca’s Nexium Approved by NMPA for Adolescent GERD Treatment

Fineline Cube Dec 30, 2022

UK-based pharmaceutical major AstraZeneca (NASDAQ: AZN) has announced receiving market approval from the National Medical...

Company Deals

Sino Biopharmaceutical Secures Rights to Shionogi’s COVID-19 Therapy Ensitrelvir

Fineline Cube Dec 30, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia Tai Tianqing...

Posts pagination

1 … 524 525 526 … 610

Recent updates

  • Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal
  • Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%
  • Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic
  • Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination
  • Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Company Drug

Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic

Company Drug

Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.